[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@_Biotech_iQ Biotech iQ

Biotech iQ posts on X about sleeper, $vtyx, $abvx, all the the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

X Week XXXXXX +88%
X Month XXXXXX +149%
X Months XXXXXX -XX%
X Year XXXXXXX +127%

Mentions: X #

X Week X -XX%
X Month XX +25%
X Months XX -XX%
X Year XXX +125%

Followers: XXXXX #

X Week XXXXX +5.40%
X Month XXXXX +16%
X Months XXXXX +29%
X Year XXXXX +194%

CreatorRank: XXXXXXX #

Social Influence

Social category influence stocks XXXX% cryptocurrencies XXXX%

Social topic influence sleeper #261, $vtyx 23.08%, $abvx 23.08%, all the 23.08%, i am #1601, $advm 7.69%, $lly 7.69%, bloomberg 7.69%, $vtyxs 7.69%, $swtx XXXX%

Top accounts mentioned or mentioned by @fwcweather @gantosjs @avidresearch @longroaderstar @stunningfeline

Top assets mentioned Adverum Biotechnologies, Inc. Common Stock (ADVM) Eli Lilly and Company (LLY) SpringWorks Therapeutics, Inc. Common Stock (SWTX) Dawn Protocol (DAWN)

Top Social Posts

Top posts by engagements in the last XX hours

"$ADVM $LLY Is it just me or does the ADVM deal smell a little like desperation"
X Link 2025-10-24T13:29Z 2441 followers, 2572 engagements

"Per Bloomberg the House passed a Bill to extend the PRV program for rare pediatric diseases. The Bill still needs to be approved by the Senate. I know many people feel the PRV program is a giveaway to pharma but I consider it to be an important part of the ecosystem and I thought it was unfortunate that Congress allowed it to expire. Hopefully the Bill passes in the Senate"
X Link 2025-12-03T04:58Z 2446 followers, 2286 engagements

"The hypothesis which remains unproven pending further data is that $VTYX's VTX002 is highly selective for S1P1 vs other subtypes thus preserving immune function vs less selective S1P inhibitors"
X Link 2025-12-06T18:54Z 2440 followers, XXX engagements

"$VTYX $ABVX All the attention is on VTYX's NLRP3 pipeline but I still think VTX002 could be an underappreciated sleeper asset. This is a quick-and-dirty comparison so I might have missed something (feedback welcome). Full disclosure: I am long VTYX (Adj c/b $.37 which is inclusive of prior trading profits.)"
X Link 2025-12-06T17:36Z 2477 followers, XXX engagements

"$AUTL $DAWN $DCTH $EDAP $SWTX"
X Link 2025-01-13T13:32Z 2478 followers, 2118 engagements

"$EVTL While biotech and medtech names remain my primary focus at Biotech iQ I also share several of my non-biotech ideas with members in chat. I shared EVTL with members back in October (see post). Recently insiders increased their holdings by over XX% through open market share purchases. And today the company unveiled its latest aircraft: the Valo along with new partnerships in the UK and France. Despite the recent run shares remain very inexpensive compared to peers. The biggest overhang (IMO) is that the company still needs to strengthen the balance sheet which adds a degree of risk. I"
X Link 2025-12-10T01:29Z 2480 followers, 1167 engagements

"$KURA $SNDX There has been a lot of debate around Zif vs. Rev so I thought I'd share this chart I prepared for BiQ members which summarizes my view of the most recent data for both drugs in the 1L chemo-ineligible setting. To make the comparison more even I am selecting for mNPM1 populations only. There is a lot more data to come so it's too early to draw any final conclusions; however I hope this helps provide some clarity. Full disclosure I am long KURA at BiQ (ACB $5.73)"
X Link 2025-12-11T02:20Z 2480 followers, 8186 engagements

"$MDNAF $MDNA Medicenna has been a sleeper position for me one of those that I buy and tuck away for the future. Today's ESMO release prompted me to refresh my thesis to see if I still wanted to continue holding. Not only did I decide to continue holding I added to my position on the selloff. True we're still talking about a small number of patients but the mechanistic thesis makes sense and the data produced to date backs it up. MDNA11 a highly differentiated beta-gamma non-alpha selective IL-2 has potential across a wide variety of solid tumors as both a monotherapy and in combination (most"
X Link 2025-12-11T04:31Z 2480 followers, 1373 engagements